Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases

References

• BaysHSteinEAPharmacotherapy for dyslipidemia-current therapies and future agentsExpert Opin Pharmacother200341901193814596646
   PubMed Web of Science ®Google Scholar
• GordonTCastelliWPHjortlandMCKannelWBDawberTRHigh density lipoprotein as a protective factor against coronary heart disease. The Framingham StudyAm J Med197762707714193398
   PubMed Web of Science ®Google Scholar
• JafriHAlsheikh-AliAAKarasRHMeta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular riskAnn Intern Med201015380080821173414
   PubMed Web of Science ®Google Scholar
• ArsenaultBJBarterPDeMiccoDAPrediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkersJ Am Coll Cardiol201157636921185503
   PubMed Web of Science ®Google Scholar
• JohnsenSHMathiesenEBFosseEElevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis the Tromsø studyCirculation200511249850416027250
   PubMed Web of Science ®Google Scholar
• WeiLMurphyMJMacDonaldTMImpact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugsHeart20069274675116216856
   PubMed Web of Science ®Google Scholar
• RubinsHBRobinsSJCollinsDGemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterolN Engl J Med199934141041810438259
   PubMed Web of Science ®Google Scholar
• ShepherdJBetteridgeJVan GaalLNicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus PanelCurr Med Res Opin20052166568215969866
   PubMed Web of Science ®Google Scholar
• TallARPlasma cholesteryl ester transfer proteinJ Lipid Res199334125512748409761
   PubMed Web of Science ®Google Scholar
• MarcelYLMcPhersonMHogueHDistribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjectsJ Clin Invest19908510172295691
   PubMed Web of Science ®Google Scholar
• HaYCGorjatschkoLBarterPJChanges in the density distribution of pig high density lipoproteins during incubation in vitro. Influence of esterified cholesterol transfer activityAtherosclerosis1983482532636639707
   PubMed Web of Science ®Google Scholar
• ParomovVMMortonRELipid transfer inhibitor protein defines the participation of high-density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP)J Biol Chem2003278408594086612907677
   PubMed Web of Science ®Google Scholar
• BarterPJBrewerHBJrChapmanJCholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosisArterioscler Thromb Vas Biol200323160167
   PubMed Web of Science ®Google Scholar
• De GroothGJKuivenhovenJAStalenhoefAFEfficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose–response studyCirculation2002105212159216511994249
   PubMed Web of Science ®Google Scholar
• KuivenhovenJADe GroothGJKawamuraHEffectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemiaAm J Cardiol2005951085108815842977
   PubMed Web of Science ®Google Scholar
• KrishnaRAndersonMSBergmanAJEffect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studiesLancet20073701907191418068514
   PubMed Web of Science ®Google Scholar
• BloomfieldDCarlsonGLSapreAEfficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patientsAm Heart J2008157235236019185645
   PubMed Web of Science ®Google Scholar
• NichollsSJBrewerHBKasteleinJJPEffects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statin on HDL and LDL cholesterol. A randomized controlled trialJAMA2011306192099210922089718
   PubMed Web of Science ®Google Scholar
• FayadZAManiVWoodwardMSafety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomized clinical trialLancet20113781547155921908036
   PubMed Web of Science ®Google Scholar
• CannonCPShahSDanskyHMSafety of anacetrapib in patients with or at high risk for coronary heart diseaseNew Engl J Med2010363252406241521082868
   PubMed Web of Science ®Google Scholar
• DavidsonMHUpdate on CETP inhibitionJ Clin Lipidology201045394398
   PubMed Web of Science ®Google Scholar
• MiyaresMAAnacetrapib and Dalcetrapib: Two novel cholesteryl ester transfer protein inhibitorsAnn Pharmacother2011451849421205945
   PubMed Web of Science ®Google Scholar
• OkamotoHYonemoriFWakitaniKMinowaTMaedaKShinkaiHA cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbitsNature2000406679220320710910363
   PubMed Web of Science ®Google Scholar
• QuiXMistryAAmmiratiMJCrystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid moleculesNat Struct Mol Biol200714210611317237796
   PubMed Web of Science ®Google Scholar
• NiesorEJMaggCOgawaNModulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transportJ Lipid Res2010513443345420861162
   PubMed Web of Science ®Google Scholar
• LüscherTDalcetrapib passed test in dal-VESSEL: Raises HDL cholesterol but not blood pressureEuropean Society of Cardiology CongressAugust 29, 2011Paris
   Google Scholar
• SchwartzGGOlssonAGBallantyneCMRationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndromeAm Heart J200915889690119958854
   PubMed Web of Science ®Google Scholar
• BarterPJCaulfieldMErikssonMEffects of torcetrapib in patients at high risk for coronary eventsN Engl J Med20073572109212217984165
   PubMed Web of Science ®Google Scholar
• RaderDJIlluminating HDL – Is it still a viable therapeutic target?N Engl J Med20073572180218317984168
   PubMed Web of Science ®Google Scholar
• VergeerMBotsMLvan LeuvenSICholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity. A pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trialsCirculation2008118252515252219029469
   PubMed Web of Science ®Google Scholar
• KasteleinJJvan LeuvenSIBurgessLEffect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemiaN Engl J Med20073561620163017387131
   PubMed Web of Science ®Google Scholar
• BotsMLVisserenFLEvansGWTorcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trialLancet200737015316017630038
   PubMed Web of Science ®Google Scholar
• HuXDietzJDXiaCTorcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibitionEndocrinology20091502211221919164467
   PubMed Web of Science ®Google Scholar
• StroesESKasteleinJJBenardeauADalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in ratsBr J Pharmacol20091581763177019917065
   PubMed Web of Science ®Google Scholar
• ShinkaiHCholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agentsExpert Opin Ther Patents200919912291237
   PubMed Web of Science ®Google Scholar
• GutsteinDEKrishnaRJohnsDAnacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reductionClin Pharmacol Ther201291110912222130116
   PubMed Web of Science ®Google Scholar
• ClarkRWRuggeriRBCunninghamDDescription of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of actionJ Lipid Res200647536552
   Web of Science ®Google Scholar
• ForrestMJBloomfieldDBriscoeRJTorcetrapib-induced blood pressure elevation is independent of cholesteryl ester transfer protein inhibition and is accompanied by an increase in circulating aldosterone levelsBr J Pharmacol20081541465147318536749
   PubMed Web of Science ®Google Scholar